Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,323 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 |
| clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT01933945 | Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib(OPTIMIS) | completed | — | 1,676 | BayerINDUSTRY | 31 | Nov 6, 2018 | clinicaltrials |
| NCT02865148 | Behavioral Symptom Management Program for Breast Cancer in Singapore and The US | completed | N/A | 40 | Duke-NUS Graduate Medical SchoolOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT03414450 | Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | withdrawn | Phase 1 | 0 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 2 | Oct 25, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT01810770 | Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis | completed | Phase 3 | 243 | BayerINDUSTRY | 4 | Sep 19, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT01022723 | Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells(CTC) | unknown | — | 817 | National Cancer Centre, SingaporeOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01064349 | Breast Cancer With Over-expression of erbB2-BRAINSTORM | completed | — | 144 | GlaxoSmithKlineINDUSTRY | 3 | Sep 14, 2018 | clinicaltrials |
| NCT01540110 | Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses | completed | Phase 2 | 21 | National Cancer Centre, SingaporeOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT02507154 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer(NKEXPHNC) | unknown | Phase 1 / Phase 2 | 31 | National University Hospital, SingaporeOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT03594929 | Effect of Remote Ischaemic preConditioning on Liver Injury in Patients Undergoing LIVER Resection Surgery | unknown | N/A | 50 | Singapore General HospitalOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT03090139 | Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets | completed | — | 1,731 | TakedaINDUSTRY | 10 | Jun 26, 2018 | clinicaltrials |
| NCT01248897 | Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib(BioPATH) | completed | — | 158 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT01462604 | Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer | completed | — | 27 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT03143036 | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 4 | Jun 7, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT03405454 | A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas | unknown | Phase 2 | 46 | National University Hospital, SingaporeOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT02158702 | Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03518957 | 12-week Exercise Intervention Program Versus Observation in Early Stage Breast Cancer Patients on the Impact on Mental Health, Quality of Life and Immune Markers | unknown | Phase 3 | 304 | National University Hospital, SingaporeOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT01135056 | Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)(SIRveNIB) | unknown | Phase 3 | 360 | Singapore General HospitalOTHER | 12 | Apr 24, 2018 | clinicaltrials |
| NCT01341834 | Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors | unknown | Phase 1 | 49 | National Cancer Centre, SingaporeOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00758186 | Randomized Trial of Colonic Stents as a Bridge to Surgery | completed | Phase 3 | 40 | Singapore General HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT03499626 | Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 22 | National University Hospital, SingaporeOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03081312 | A Study of Family Caregivers' Needs, Burden of Care and Quality of Life Over the Course of a Cancer Illness(FCG-NBC) | unknown | — | 510 | National University of SingaporeOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT02313298 | Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer | unknown | Phase 2 | 80 | National Cancer Centre, SingaporeOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT02801734 | Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer(EQUIP) | completed | N/A | 69 | National Cancer Centre, SingaporeOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03188159 | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer | unknown | Phase 2 | 36 | National University Hospital, SingaporeOTHER | 2 | Mar 29, 2018 | clinicaltrials |
| NCT01024036 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | completed | Phase 2 | 79 | Janssen Research & Development, LLCINDUSTRY | 23 | Mar 21, 2018 | clinicaltrials |
| NCT03429972 | Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | unknown | Phase 2 | 51 | National Cancer Centre, SingaporeOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT03412955 | A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes | unknown | Phase 2 | 14 | Tan Tock Seng HospitalOTHER | 2 | Feb 27, 2018 | clinicaltrials |
| NCT00089973 | Study Of Ispinesib In Subjects With Breast Cancer | completed | Phase 2 | 50 | GlaxoSmithKlineINDUSTRY | 5 | Feb 26, 2018 | clinicaltrials |
| NCT03435770 | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | unknown | N/A | 10 | Singapore General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01728311 | Open Label Study of BAY1082439 in Patients With Advanced Cancer | completed | Phase 1 | 60 | BayerINDUSTRY | 3 | Jan 30, 2018 | clinicaltrials |
| NCT02042144 | Safety and Effectiveness of Regorafenib(Correlate) | completed | — | 1,034 | BayerINDUSTRY | 13 | Jan 16, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials